Plain-English translation of NCT07046078 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment plan called FLAG-Ida followed by a reduced-intensity stem cell transplant for older adults with newly diagnosed, aggressive blood cancers like acute myeloid leukemia. The first part of the treatment uses three chemotherapy drugs (, , and ) given intravenously over several days. After the chemotherapy, you receive mild radiation and then a transplant of healthy blood-forming stem cells from a matched donor to help rebuild your immune system and fight the cancer.
Current treatments for aggressive blood cancers in older adults have limited success, and standard stem cell transplants are often too intense for people over 60. This trial is testing whether a gentler version of this transplant approach might work better for older patients while being safer and more tolerable.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy as an inpatient or outpatient over several days, followed by mild radiation therapy and then an infusion of donated stem cells on day 0 or 1. The entire treatment takes place over about a week, after which you will have frequent follow-up visits and monitoring—at days 28, 56, and 80, then at months 3 and 6, and at years 1 and 2. During your stay and follow-up appointments, you will have blood tests, bone marrow biopsies, heart imaging, and physical exams to monitor how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States